MX2016015552A - Osteoclast inhibitors for pain. - Google Patents

Osteoclast inhibitors for pain.

Info

Publication number
MX2016015552A
MX2016015552A MX2016015552A MX2016015552A MX2016015552A MX 2016015552 A MX2016015552 A MX 2016015552A MX 2016015552 A MX2016015552 A MX 2016015552A MX 2016015552 A MX2016015552 A MX 2016015552A MX 2016015552 A MX2016015552 A MX 2016015552A
Authority
MX
Mexico
Prior art keywords
pain
osteoclast inhibitors
osteoclast
inhibitors
methods
Prior art date
Application number
MX2016015552A
Other languages
Spanish (es)
Inventor
Tabuteau Herriot
K M Dinkla Eric
Jones Graeme
Original Assignee
Antecip Bioventures Ii Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/288,241 external-priority patent/US8901161B1/en
Priority claimed from US14/288,720 external-priority patent/US8865757B1/en
Priority claimed from US14/288,716 external-priority patent/US8835650B1/en
Priority claimed from US14/310,811 external-priority patent/US8822436B1/en
Priority claimed from PCT/US2014/050427 external-priority patent/WO2015060924A1/en
Priority claimed from US14/457,659 external-priority patent/US20140349974A1/en
Priority claimed from US14/495,732 external-priority patent/US9127069B1/en
Priority claimed from US14/530,556 external-priority patent/US20150051175A1/en
Priority claimed from US14/536,526 external-priority patent/US20150057250A1/en
Priority claimed from US14/604,524 external-priority patent/US9211257B2/en
Priority claimed from US14/608,855 external-priority patent/US9079927B1/en
Priority claimed from US14/625,457 external-priority patent/US9427403B2/en
Priority claimed from US14/639,013 external-priority patent/US9289441B2/en
Application filed by Antecip Bioventures Ii Llc filed Critical Antecip Bioventures Ii Llc
Priority claimed from PCT/US2015/032739 external-priority patent/WO2015184003A1/en
Publication of MX2016015552A publication Critical patent/MX2016015552A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Abstract

Methods for the safe administration of imidazole or imidazolium compounds, and conditions that may be treated by these methods, are described herein.
MX2016015552A 2014-05-27 2015-05-27 Osteoclast inhibitors for pain. MX2016015552A (en)

Applications Claiming Priority (28)

Application Number Priority Date Filing Date Title
US14/288,241 US8901161B1 (en) 2014-05-27 2014-05-27 Therapeutic compositions comprising imidazole and imidazolium compounds
US14/288,720 US8865757B1 (en) 2014-05-28 2014-05-28 Therapeutic compositions comprising imidazole and imidazolium compounds
US14/288,716 US8835650B1 (en) 2014-01-30 2014-05-28 Substituted imidazolium compounds for treating disease
US14/288,713 US8901162B1 (en) 2014-01-30 2014-05-28 Substituted imidazolium compounds for treating disease
US201462012112P 2014-06-13 2014-06-13
US14/310,811 US8822436B1 (en) 2012-05-14 2014-06-20 Compositions for oral administration of zoledronic acid or related compounds for treating disease
US14/336,642 US20140329773A1 (en) 2012-05-14 2014-07-21 Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Disease
US14/446,184 US9006279B1 (en) 2014-01-30 2014-07-29 Substituted imidazolium compounds for treating disease
PCT/US2014/050427 WO2015060924A1 (en) 2013-10-25 2014-08-08 Compositions for oral administration of zoledronic acid or related compounds for treating disease
US14/457,659 US20140349974A1 (en) 2014-08-12 2014-08-12 Zoledronic acid dosage forms for the treatment of pain
US14/481,097 US8962599B1 (en) 2014-05-27 2014-09-09 Therapeutic compositions comprising imidazole and imidazolium compounds
US201462053619P 2014-09-22 2014-09-22
US14/495,732 US9127069B1 (en) 2014-06-11 2014-09-24 Compositions comprising rank/rankl antagonists and related compounds for treating pain
US14/530,556 US20150051175A1 (en) 2012-05-14 2014-10-31 Co-Administration of Steroids and Zoledronic Acid to Prevent and Treat Pain
US14/536,526 US20150057250A1 (en) 2012-05-14 2014-11-07 Inhibitors of osteoclast activity for treating arthritis
US14/538,709 US9290575B2 (en) 2014-06-11 2014-11-11 Compositions comprising RANK/RANKL antagonists and related compounds for treating pain
US14/540,333 US9216168B1 (en) 2014-05-27 2014-11-13 Therapeutic compositions comprising imidazole and imidazolium compounds
US14/604,524 US9211257B2 (en) 2012-05-14 2015-01-23 Osteoclast inhibitors for knee conditions
US14/605,822 US9216153B2 (en) 2012-05-14 2015-01-26 Osteoclast inhibitors for knee conditions
US14/607,947 US9289384B2 (en) 2012-05-14 2015-01-28 Osteoclast inhibitors for knee conditions
US14/607,985 US9289385B2 (en) 2012-05-14 2015-01-28 Osteoclast inhibitors for knee conditions
US14/608,855 US9079927B1 (en) 2014-05-27 2015-01-29 Substituted imidazolium compounds for treating disease
US14/625,457 US9427403B2 (en) 2012-05-14 2015-02-18 Methods for the safe administration of imidazole or imidazolium compounds
US201562127214P 2015-03-02 2015-03-02
US14/635,857 US9283239B2 (en) 2012-05-14 2015-03-02 Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US14/639,013 US9289441B2 (en) 2014-08-08 2015-03-04 Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US14/686,551 US9408860B2 (en) 2012-05-14 2015-04-14 Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
PCT/US2015/032739 WO2015184003A1 (en) 2014-05-27 2015-05-27 Osteoclast inhibitors for pain

Publications (1)

Publication Number Publication Date
MX2016015552A true MX2016015552A (en) 2018-01-12

Family

ID=57681122

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015552A MX2016015552A (en) 2014-05-27 2015-05-27 Osteoclast inhibitors for pain.

Country Status (8)

Country Link
EP (1) EP3148534A4 (en)
JP (2) JP6457555B2 (en)
KR (4) KR101975645B1 (en)
AU (1) AU2015267046C1 (en)
IL (1) IL249234A0 (en)
MX (1) MX2016015552A (en)
NZ (1) NZ726690A (en)
SG (3) SG10201706414SA (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7875597B2 (en) * 2002-07-24 2011-01-25 New York University Treatment of spinal mechanical pain
CN103153328A (en) * 2010-07-16 2013-06-12 默克专利股份有限公司 Peptide for use in the treatment of breast cancer and/or bone metastases
US8802658B2 (en) * 2012-05-14 2014-08-12 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
PT2849758T (en) * 2012-05-14 2018-05-09 Antecip Bioventures Ii Llc Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions

Also Published As

Publication number Publication date
EP3148534A1 (en) 2017-04-05
AU2015267046A1 (en) 2016-12-15
JP2017516788A (en) 2017-06-22
SG10201706414SA (en) 2017-09-28
NZ726690A (en) 2018-03-23
AU2015267046C1 (en) 2018-10-25
JP6457555B2 (en) 2019-01-23
KR20170005872A (en) 2017-01-16
AU2015267046B2 (en) 2018-07-19
KR20210149861A (en) 2021-12-09
KR20210038700A (en) 2021-04-07
SG11201609767PA (en) 2016-12-29
EP3148534A4 (en) 2018-01-24
KR20190010728A (en) 2019-01-30
SG10201906609UA (en) 2019-08-27
JP2019069979A (en) 2019-05-09
KR101975645B1 (en) 2019-05-07
KR102409599B1 (en) 2022-06-22
IL249234A0 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
GB2541571A (en) Pharmaceutical compositions
MX2018006578A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions.
EA201591509A1 (en) CDC7 INHIBITORS
MX2017003516A (en) Pyrazole derivatives as sgc stimulators.
NZ724691A (en) Quinoline derivatives as smo inhibitors
EA201791133A1 (en) ERK INHIBITORS
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2018006632A (en) Bicyclic inhibitors of pad4.
MX2018006700A (en) Aza-benzimidazole inhibitors of pad4.
MX2017000306A (en) Methods for treating hypotension.
EP3226972A4 (en) Methods and compositions for treating migraine and conditions associated with pain
MX2017016114A (en) Methods of treating or preventing a proteopathy.
HK1244211A1 (en) Method for treating, preventing, or reducing the risk of skin infection
NZ722600A (en) Methods of treating mild brain injury
ZA201703467B (en) Methods of treating ocular conditions
MX2020009966A (en) Dosage forms and therapeutic uses l-4-chlorokynurenine.
MX2016009655A (en) Novel methods for treating cancer.
MX2018005987A (en) Heterocyclic compounds for the treatment of disease.
MX2021006326A (en) Pcna inhibitors.
JO3541B1 (en) Medical treatments based on anamorelin
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
MX2021008225A (en) Compositions and methods for treatment of abnormal cell growth.
EP3193610A4 (en) Selective nav1.7 inhibitors for the treatment of diabetes
MX2017007318A (en) Methods of preventing, reducing or treating macular degeneration.